Staging Of Uterine Cancer

ADVERTISEMENT

As with other cancers, it is very important to complete all the above mentioned tests before embarking on any cancer treatment. Sometimes a woman may be irate with the specialist as the diagnosis may already be known from the histology of the dilatation and curretage (uterine cancer), but the cancer stage has yet to be determined. The specialist needs to explain to the woman that depending on what stage is found the treatment can be radically different and this is the reason why there is no room for short-cuts.

In the past, particularly with uterine cancer the work-up was not that thorough often neglecting to look for possible pelvic metastases. As a result a simple hysterectomy was done leaving pelvic or paraaortic lymph glands untreated. Of course, this led to very disappointing survival data. With proper investigation this would never have happened. Cancer is very unforgiving and there is no room for errors.

The revised FIGO staging (1988, slightly modified in 2000) is what is used in the major Cancer Clinics throughout the U.S.:

Staging of uterine cancer (FIGO classification)
Stage: Description of extent of uterine cancer:
IA tumor limited to lining of uterus
IB invasion to ‹ 1/2 thickness of lining
IC invasion to › 1/2 thickness of lining
IIA invasion into cervical lymph glands
IIB invasion of cervical tissue
IIIA invasion of ovaries, positive peritoneal cytology
IIIB vaginal metastases
IIIC pelvic or paraaortic LN * 
IVA invasion of bladder or bowel
IVB distant or abdominal metastases, also inguinal LN
* stands for "lymph node metastases"

  Apart from the stage of the tumor, which is determined by the depth of invasion and the spread into neighboring structures, the patient's survival also depends on what histological type the tumor is. This is called the "grade" of the tumor. It determines how aggressive the growth pattern will be.

Home page Cancer overview Uterine Cancer

Histological grading and tumor behavior of uterine cancer

Histological grading of uterine cancer
Grade: Description:
1 well-differentiated
2 moderately differentiated
3 poorly differentiated

Many different investigators from the U.S. and elsewhere have found that groups of women with uterine cancer divide usually into about 40% with grade 1, 40% with grade 2 and 20% with grade 3 disease. This has practical implications as particularly grade 3 tumors, which consist of rapidly dividing immature cancer cells, tend to metastasize early into lymph glands of the pelvis or into the paraaortic lymph nodes. The physician will therefore take particular care to look for hidden metastases in order to develop a treatment plan that is appropriate for this patient (Ref.1, page 1197). Radiotherapy will be included in these cases to cover for pelvic and paraaortic lymph gland metastases.

Home page Cancer overview Uterine Cancer

Tumor growth behavior

ADVERTISEMENT

The lining of the uterus (called "endometrium" by doctors) goes through similar cell changes in the development of cancer as is the case in cervical cancer, where I described this process in detail.

The equivalent for "dysplasia" in cancer of the cervix would be called "atypical adenomatous hyperplasia" in uterine cancer. I would not want you to remember that, but understand the principal that there are warning signs that tell the gynecologist, when an endometrial biopsy is done, that this type of change will go on to develop into uterine cancer. Since the early 1990's endometrial biopsies have become a more common procedure and this can significantly determine the risk for uterine cancer development down the road (see below).  

 Once cancer of the uterus is established, it has the tendency to grow along the uterine cavity down into the cervix and also towards the fallopian tubes. The cancer cells produce lytic enzymes, which enable the cancer also to eat its way slowly through the uterine wall. Frequently the cancer invades the ovaries, the uterine support ligaments (called "broad ligament"), the vagina and the pelvic lymp nodes. Next the cancer cells spread further through the lymphatic passages into the paraaortic lymph nodes and into the blood stream.

From here any organ can be metastasized. Inside the abdomen the cancer cells shed into the peritoneal cavity from either the fallopian tube, an invasion through the uterus or through an ovarian metastasis. The cells can also migrate through lymphatic migration channels (described in more detail in the ovarian cancer chapter) into the liver, the right lung or into retroperitoneal lymph glands. There is another channel for metastases to migrate through and this is along the round ligaments (a uterine ligamentous support to the front of the lower abdominal wall) and through lymphatic connnections to the thigh lymph nodes (called" femoral nodes"). If there are lumps under the skin of the upper front thigh region in a woman with uterine cancer, this is not a good sign: it is associated with a very poor survival rate.

  It can be difficult to establish the stage of uterine cancer. Sometimes it appears that only 10% of the pelvic lymph glands would be affected. However, autopsy studies showed later that much more invasive disease was present with 65% of pelvic metastases (Ref. 1, p. 1196).

Home page Cancer overview Uterine Cancer


 

ADVERTISEMENT

ADVERTISEMENT

Disclaimer:

This outline is only a teaching aid to patients and should stimulate you to ask the right questions when seeing your doctor. However, the responsibility of treatment stays in the hands of your doctor and you.

References:

1. Cancer: Principles &Practice of Oncology.4th edition. Edited by Vincent T. DeVita, Jr. et al. Lippincott, Philadelphia,PA, 1993. Vol. 1. Chapter on gynecological tumors.

2. Cancer: Principles&Practice of Oncology. 5th edition, volume 1. Edited by Vincent T. DeVita, Jr. et al. Lippincott-Raven Publ., Philadelphia,PA, 1997. Chapter on gynecological tumors.

3. B. Sears: "The age-free zone". Regan Books, Harper Collins, 2000.

4. E Weiderpass et al. Cancer Causes Control 2000 Feb;11(2):185-192.

5. S Shibutani et al. Cancer Res 2001 May 15;61(10):3925-3931.

6. DB Fournier et al. Gynecol Oncol 2001 Jun;81(3):366-372.

7. DS McMeekin et al. Gynecol Oncol 2001 May;81(2):273-278.

8. LA Katz et al. Am J Obstet Gynecol 2001 May;184(6):1071-1073.

9. B Bonanni et al. Breast J 2000 Oct;6(5):317-323.

10. MG Jain et al. Eur J Epidemiol 2000;16(10):899-905.

11. Conn's Current Therapy 2004, 56th ed., Copyright © 2004 Elsevier

12. Ferri: Ferri's Clinical Advisor: Instant Diagnosis and Treatment, 2004 ed., Copyright © 2004 Mosby, Inc

Last Modified: Jan. 27, 2008

Links ManagerHealth LinksWe subscribe to the HONcode principles of the HON Foundation. Click to verify. width=

Copyright © 2007 NetHealth Holdings Inc.
Site Design by: Polar Sky Media | All Rights Reserved